-
1.发明授权Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途公开(公告)号：US08101180B2
公开(公告)日：2012-01-24
申请号：US12388534
申请日：2009-02-19
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
IPC分类号： A61K39/00 , A61K39/395 , A61K51/10 , G01N33/53 , G01N33/574 , G01N33/561 , G01N33/557 , G01N33/566
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人胰岛素样生长因子I受体（IGF-1R）和/或胰岛素/ IGF-I杂合受体（杂合-R）和/或能够特异性抑制 所述IGF-1R和/或杂种-R，特别是鼠，嵌合和人源化起始的单克隆抗体以及编码这些抗体的氨基酸和核酸序列的酪氨酸激酶活性。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R和/或杂合-R的癌症或与所述受体的过度表达相关的任何病理学以及在用于 诊断与IGF-1R和/或杂合体R的过表达相关的疾病。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
2.发明申请Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies 审中-公开用于治疗牛皮癣的方法，其包含新的抗IGF-1R抗体公开(公告)号：US20080063639A1
公开(公告)日：2008-03-13
申请号：US11783666
申请日：2007-04-11
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck , Yann Duflos
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck , Yann Duflos
IPC分类号： A61K39/395 , A61P17/06
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to a method for the prevention or for the treatment of psoriasis comprising administering to a patient in need thereof an effective amount of an isolated antibody, or one of its functional fragments, capable of binding to the human insulin-like growth factor I receptor IGF-IR. The present invention is also directed to said method wherein a second compound selected from the compounds capable of specifically inhibiting the attachment of the EGF to the human epidermal growth factor receptor EGFR, such as an isolated anti-EGFR antibody, or a functional fragment thereof, is administered to the patient in addition to the anti-IGR-IR antibody.
摘要翻译： 本发明涉及一种预防或治疗牛皮癣的方法，包括向有需要的患者施用有效量的能够结合人类胰岛素样生长因子的分离抗体或其功能片段之一 I受体IGF-1R。 本发明还涉及所述方法，其中选自能够特异性抑制EGF与人表皮生长因子受体EGFR（例如分离的抗EGFR抗体或其功能片段）附着的化合物的第二化合物， 除了抗IGR-IR抗体外还施用于患者。
-
3.发明授权Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途公开(公告)号：US07553485B2
公开(公告)日：2009-06-30
申请号：US11012353
申请日：2004-12-16
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人胰岛素样生长因子I受体（IGF-1R）和/或胰岛素/ IGF-I杂合受体（杂合-R）和/或能够特异性抑制 所述IGF-1R和/或杂种-R，特别是鼠，嵌合和人源化起始的单克隆抗体以及编码这些抗体的氨基酸和核酸序列的酪氨酸激酶活性。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R和/或杂合-R的癌症或与所述受体的过度表达相关的任何病理学以及在用于 诊断与IGF-1R和/或杂合体R的过表达相关的疾病。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
4.发明申请NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF 有权新型抗IGF-1R和/或抗胰蛋白胨/ IGF-I混合受体抗体及其用途公开(公告)号：US20120208721A1
公开(公告)日：2012-08-16
申请号：US13352599
申请日：2012-01-18
申请人： Liliane GOETSCH , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane GOETSCH , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.
摘要翻译： 本发明涉及鉴定IGF-1R调节剂和杂合-R调节剂的方法，其包括将IGF-1R与人源化抗IGF-1R抗体接触并分别使杂交-R与人源化抗混合-R抗体接触。
-
5.发明申请NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF 有权新型抗IGF-1R和/或抗胰蛋白胨/ IGF-I混合受体抗体及其用途公开(公告)号：US20110014122A1
公开(公告)日：2011-01-20
申请号：US12388534
申请日：2009-02-19
申请人： Liliane GOETSCH , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane GOETSCH , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人胰岛素样生长因子I受体（IGF-1R）和/或胰岛素/ IGF-I杂合受体（杂合-R）和/或能够特异性抑制 所述IGF-1R和/或杂种-R，特别是鼠，嵌合和人源化起始的单克隆抗体以及编码这些抗体的氨基酸和核酸序列的酪氨酸激酶活性。 本发明同样包括使用这些抗体作为预防和/或治疗过度表达IGF-1R和/或杂合-R的癌症或与所述受体的过度表达相关的任何病理学以及用于 诊断与IGF-1R和/或杂合体R的过表达相关的疾病。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
6.发明申请Novel anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权新型抗IGF-1R和/或抗胰岛素/ IGF-I杂合体受体抗体及其用途公开(公告)号：US20050249730A1
公开(公告)日：2005-11-10
申请号：US11012353
申请日：2004-12-16
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
IPC分类号： A61K47/48 , A61K39/395 , C07K16/30
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人胰岛素样生长因子I受体（IGF-1R）和/或胰岛素/ IGF-I杂合受体（杂合-R）和/或能够特异性抑制 所述IGF-1R和/或杂种-R，特别是鼠，嵌合和人源化起始的单克隆抗体以及编码这些抗体的氨基酸和核酸序列的酪氨酸激酶活性。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R和/或杂合-R的癌症或与所述受体的过度表达相关的任何病理学以及在用于 诊断与IGF-1R和/或杂合体R的过表达相关的疾病。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
7.发明授权Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途公开(公告)号：US08808999B2
公开(公告)日：2014-08-19
申请号：US13352599
申请日：2012-01-18
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.
摘要翻译： 本发明涉及鉴定IGF-1R调节剂和杂合-R调节剂的方法，其包括将IGF-1R与人源化抗IGF-1R抗体接触并分别使杂交-R与人源化抗混合-R抗体接触。
-
公开(公告)号：US20080286198A1
公开(公告)日：2008-11-20
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
IPC分类号： A61K51/10 , C07H21/04 , C12N15/63 , C12N5/06 , A01K67/027 , C12P21/00 , G01N33/53 , C07K16/28 , A61K39/395 , A61P35/00 , A61K39/44
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
-
公开(公告)号：US20050084906A1
公开(公告)日：2005-04-21
申请号：US10735916
申请日：2003-12-16
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。
-
公开(公告)号：US20120156191A1
公开(公告)日：2012-06-21
申请号：US13310840
申请日：2011-12-05
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/92
摘要： The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening.More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.
摘要翻译： 本发明涉及能够在体外和/或体内抑制肿瘤细胞增殖并通过功能筛选获得的新型分离的抗体，衍生化合物和功能性分离的抗体片段。 更具体地，本发明涉及对JAM-A蛋白特异的6F4抗体及其用于治疗癌症的用途。 也涵盖由这些抗体组成的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.033 秒)
